NPH Insulin (Isophane): Complete Drug Monograph

Pharmacokinetic Profile

Half-Life

~4.4 h (apparent, SC)

Onset

1–3 hours

Peak Effect

4–12 hours

Duration

Up to 24 hours

Metabolism

Liver, kidney, muscle

Protein Binding

Low (variable)

Clinical Information

Drug Class

Intermediate-acting insulin

Available Forms

10 mL vial, 3 mL KwikPen / FlexPen

Route

Subcutaneous only

Renal Adjustment

Reduce dose; monitor closely

Hepatic Adjustment

Reduce dose; monitor closely

Pregnancy

Compatible (human insulin)

Lactation

Compatible; adjust dose

Schedule

Prescription (Rx)

Generic Available

Yes (ReliOn Novolin N available without Rx at Walmart, except Indiana)

Indications for NPH Insulin

Indication	Approved Population	Therapy Type	Status
Type 1 diabetes mellitus	Adults and pediatric patients	Basal component of multi-dose regimen (with prandial insulin)	FDA Approved
Type 2 diabetes mellitus	Adults and pediatric patients	Monotherapy or adjunctive to oral agents and/or prandial insulin	FDA Approved

NPH insulin remains a cornerstone basal insulin option, particularly where cost is a primary consideration. It provides intermediate-duration glucose-lowering coverage and can be combined with rapid-acting or regular insulin either as separate injections or as pre-mixed formulations. The ADA Standards of Care (2025/2026) acknowledge NPH insulin as a suitable basal insulin for both type 1 and type 2 diabetes, while noting that long-acting analogues carry a lower risk of nocturnal and severe hypoglycaemia compared to NPH.

Off-Label Uses

Gestational diabetes mellitus (GDM): NPH insulin is widely used as basal insulin in GDM when lifestyle modifications are insufficient. Human insulin does not cross the placenta, and NPH has extensive safety data in pregnancy. The ADA 2026 Standards list NPH as a basal insulin option in pregnancy. (Evidence quality: High)

Hyperglycaemia management in hospitalised patients (non-ICU): NPH insulin is used as the basal component of subcutaneous basal-bolus regimens for inpatient glycaemic management. (Evidence quality: Moderate)

Steroid-induced hyperglycaemia: The intermediate duration of NPH insulin makes it a practical choice for managing hyperglycaemia caused by once-daily corticosteroids, as its action profile can be matched to the steroid’s peak glucose-raising effect. (Evidence quality: Moderate)

Dose

NPH Insulin Dosing

Adult Dosing by Clinical Scenario

Clinical Scenario	Starting Dose	Maintenance Dose	Maximum Dose	Notes
T2DM — basal insulin initiation (add-on to oral agents)	0.1–0.2 units/kg/day	Titrate by 2–4 units q3–7d to fasting glucose target	Individualised (no fixed ceiling)	Give once daily at bedtime or twice daily (morning and bedtime) ADA 2025: start 10 units/day or 0.1–0.2 units/kg/day
T1DM — basal-bolus regimen (basal component)	0.2–0.4 units/kg/day	Typically 40–50% of total daily dose as NPH	0.4–1.0 units/kg/day (total insulin)	Usually given BID (morning + bedtime); pair with rapid-acting at meals Higher requirements during illness or puberty
Gestational diabetes — basal coverage for fasting hyperglycaemia	0.1–0.2 units/kg/day	Titrate q2–3d to fasting BG <95 mg/dL	Individualised (insulin requirements increase across trimesters)	Typically given at bedtime; may split BID if needed Postpartum: requirements drop sharply; reduce dose immediately
Steroid-induced hyperglycaemia — once-daily morning corticosteroid	0.1–0.3 units/kg	Titrate to afternoon/evening glucose targets	Match steroid dose changes	Give NPH with morning steroid dose; reduce NPH when steroid tapered NPH action profile matches glucose-raising curve of prednis(ol)one
Inpatient non-ICU — basal-bolus subcutaneous regimen (basal component)	0.1–0.15 units/kg BID	Adjust daily to BG targets 140–180 mg/dL	Individualised	Reduce total daily dose by ~20% if switching from IV insulin infusion Hold if patient is NPO; give correction doses as rapid-acting
Transition from long-acting analogue to NPH insulin	Same total basal units, split into 2 doses (BID)	Titrate to fasting and pre-dinner glucose	Individualised	When switching from glargine U-100 QD, reduce total by ~20% and divide BID Monitor closely for 1–2 weeks during transition

Pediatric Dosing

Clinical Scenario	Starting Dose	Maintenance Dose	Maximum Dose	Notes
T1DM — prepubertal children	0.5–0.75 units/kg/day (total)	~50% as NPH basal, BID	Individualised	Honeymoon phase may reduce requirements to <0.5 units/kg/day
T1DM — pubertal adolescents	0.7–1.0 units/kg/day (total)	~40–50% as NPH basal, BID	Up to 1.5 units/kg/day during growth spurts	Counter-regulatory hormone surges increase insulin resistance Dawn phenomenon may necessitate bedtime NPH timing

Clinical Pearl: Timing and Mixing

NPH insulin can be mixed in the same syringe with regular insulin or insulin lispro. Always draw the clear (rapid/regular) insulin first, then the cloudy NPH. Inject immediately after mixing. Pre-mixed 70/30 formulations (70% NPH / 30% regular) offer convenience but sacrifice dose flexibility. When using NPH at bedtime to control fasting glucose, consider administering at bedtime rather than with the evening meal to reduce the risk of nocturnal hypoglycaemia.

Renal and Hepatic Impairment

Clinical Scenario	Starting Dose	Maintenance Dose	Maximum Dose	Notes
Renal impairment (eGFR <60 mL/min)	Reduce by 25%	Titrate cautiously	Individualised	Decreased renal insulin clearance prolongs action; increase monitoring frequency Risk of hypoglycaemia rises significantly with CKD stages 4–5
Hepatic impairment	Reduce by 25–50%	Titrate cautiously	Individualised	Impaired hepatic gluconeogenesis and reduced insulin degradation; monitor closely

Pharmacology of NPH Insulin

Mechanism of Action

NPH insulin is a crystalline suspension of human insulin complexed with protamine and zinc in a neutral pH buffer. Following subcutaneous injection, protamine is gradually cleaved by tissue proteases, releasing insulin monomers into the systemic circulation over an intermediate time course. The released insulin binds to the insulin receptor tyrosine kinase on target tissues, triggering receptor autophosphorylation and downstream activation of the PI3K-Akt signalling cascade. This promotes translocation of GLUT4 glucose transporters to the cell surface in skeletal muscle and adipose tissue, facilitating glucose uptake. Simultaneously, NPH insulin suppresses hepatic glucose output by inhibiting glycogenolysis and gluconeogenesis, inhibits lipolysis in adipose tissue, and stimulates protein synthesis in muscle. The net effect is a reduction in circulating blood glucose that begins approximately 1–3 hours after injection, peaks between 4–12 hours, and can persist for up to 24 hours.

ADME Profile

Parameter	Value	Clinical Implication
Absorption	Onset 1–3 h; Tmax ~4 h (range 1–12 h); duration up to 24 h; subcutaneous only	Abdominal injection absorbs fastest; exercise, heat, and massage at the injection site accelerate absorption and may increase hypoglycaemia risk
Distribution	Insulin distributes into extracellular fluid; does not significantly cross the blood-brain barrier or placenta	Safe for use in pregnancy; volume of distribution is not clinically characterised for SC insulin due to absorption-rate-limited kinetics
Metabolism	Degraded predominantly by insulin-degrading enzyme (IDE) in liver (~60%), kidney (~35–40%), muscle, and adipose tissue	Hepatic or renal impairment reduces insulin clearance, increasing circulating levels and hypoglycaemia risk; dose reductions are needed
Elimination	Apparent t½ ~4.4 h (range 1–84 h) after SC administration (FDA PI); absorption-rate limited	The wide t½ range reflects variable SC absorption, not true elimination variability; the long tail explains the possibility of stacking with repeated dosing

Side Effects of NPH Insulin

≥10% Very Common

Adverse Effect	Incidence	Clinical Note
Hypoglycaemia (all grades)	Most common ADR (frequency varies with dose and regimen)	Incidence significantly higher with NPH versus long-acting analogues in clinical trials, especially nocturnal hypoglycaemia; patient education on recognition and treatment is essential
Injection site reactions (pain, erythema, pruritus)	10–20%	Usually mild and self-limiting within days; site rotation minimises occurrence; may relate to protamine content or preservatives
Weight gain	~1–4 kg in first year	Expected with insulin therapy; dietary counselling and concurrent metformin may attenuate; more pronounced with intensive regimens

1–10% Common

Adverse Effect	Incidence	Clinical Note
Lipodystrophy (lipoatrophy or lipohypertrophy)	2–5%	Results from repeated injection at the same site; lipohypertrophy alters absorption leading to erratic glucose control; consistent site rotation is preventive
Peripheral oedema	1–5%	Transient; typically occurs with insulin initiation or rapid dose escalation; related to sodium retention; usually resolves within weeks
Anti-insulin antibody formation	~5% develop measurable titres	Antibody formation is generally transient and does not appear to deteriorate glycaemic control in most patients
Visual disturbances (transient refraction changes)	1–3%	Occurs with rapid improvement in glycaemic control; resolves spontaneously over weeks; defer new spectacle prescriptions for 6–8 weeks after insulin initiation

Serious Serious (Regardless of Frequency)

Adverse Effect	Estimated Frequency	Typical Onset	Required Action
Severe hypoglycaemia (requiring third-party assistance)	1–5% of patients per year (varies by regimen intensity)	Peak insulin effect (4–12 h post-injection); nocturnal episodes common	Administer glucagon or IV dextrose; reassess regimen; consider switching to long-acting analogue if recurrent
Severe hypokalemia	Rare	Within hours of injection; higher risk with concurrent potassium-lowering agents	Monitor potassium in at-risk patients; replace potassium; can cause arrhythmia or respiratory paralysis if untreated
Anaphylaxis / severe generalised allergic reaction	Very rare (<0.01%)	Minutes to hours after injection	Discontinue NPH insulin permanently; treat with epinephrine; cross-reactivity with protamine may be relevant in patients with prior protamine exposure
Localised cutaneous amyloidosis	Rare	Months to years with repeated injection at same site	Change injection site to unaffected area; monitor closely for hypoglycaemia as absorption may be unpredictable
Transient worsening of diabetic retinopathy	Uncommon	Weeks to months after rapid glycaemic improvement	Pre-treatment retinal exam; gradual HbA1c reduction preferred; ophthalmology review if visual symptoms arise
Heart failure exacerbation (with concurrent TZD use)	Uncommon	Weeks to months	Monitor for fluid retention; reduce or discontinue TZD if heart failure signs emerge

Discontinuation Discontinuation Rates

Adults (Clinical Trials)

Low

Top reasons: Hypoglycaemia, weight gain, injection burden. NPH insulin discontinuation in clinical trials is relatively uncommon as it is typically a treatment of necessity. Many patients transition to long-acting analogues rather than stopping insulin altogether.

Switch to Analogue

Common transition

Key driver: Nocturnal hypoglycaemia and the inconvenience of BID dosing lead many clinicians to transition patients to once-daily glargine or degludec when affordable and accessible.

Reason for Discontinuation / Switch	Incidence	Context
Recurrent nocturnal hypoglycaemia	Most common reason for switch	NPH peak effect coincides with early morning hours when given at bedtime; long-acting analogues carry lower nocturnal hypo risk
Need for flexible once-daily dosing	Frequent	NPH typically requires BID dosing for 24-hour coverage; once-daily basal analogues improve adherence
Allergic reaction (localised or generalised)	Rare (<1%)	Protamine component may cause reaction; cross-sensitivity should be assessed before alternative insulin selection

Management of Hypoglycaemia

All patients on NPH insulin should carry a rapid-acting glucose source. Mild-to-moderate episodes (BG <70 mg/dL with symptoms): treat with 15–20 g fast-acting carbohydrate, recheck in 15 minutes (rule of 15). Severe episodes (unconscious or unable to swallow): administer glucagon IM/SC/intranasal. Because NPH has a prolonged action, a follow-up meal or snack with complex carbohydrate and protein is essential to prevent recurrence during the remaining duration of action.

Int

Drug Interactions with NPH Insulin

NPH insulin is not metabolised through the cytochrome P450 system, so traditional pharmacokinetic drug-drug interactions are not a concern. Instead, interactions are primarily pharmacodynamic: drugs that raise or lower blood glucose, or medications that mask hypoglycaemic symptoms, are the most clinically significant.

Major Pramlintide

MechanismAdditive glucose-lowering through delayed gastric emptying and glucagon suppression

EffectMarkedly increased hypoglycaemia risk; must not be mixed in the same syringe

ManagementReduce prandial insulin dose by 50% when initiating pramlintide; administer separately; monitor glucose closely

FDA PI

Major Thiazolidinediones (pioglitazone, rosiglitazone)

MechanismAdditive glucose-lowering plus TZD-induced fluid retention

EffectIncreased risk of heart failure, peripheral oedema, and hypoglycaemia

ManagementMonitor for signs of heart failure; consider dose reduction of insulin or TZD; discontinue TZD if HF symptoms appear

FDA PI

Moderate Beta-blockers (non-selective)

MechanismMask adrenergic symptoms of hypoglycaemia (tachycardia, tremor); may impair hepatic glucose mobilisation

EffectDelayed recognition and prolonged recovery from hypoglycaemia

ManagementPrefer cardioselective beta-blockers (metoprolol, bisoprolol); educate patient to recognise non-adrenergic hypo symptoms (confusion, hunger, diaphoresis)

FDA PI

Moderate Corticosteroids (systemic)

MechanismGlucocorticoids promote hepatic gluconeogenesis and peripheral insulin resistance

EffectHyperglycaemia; may require substantial insulin dose increases

ManagementIncrease glucose monitoring frequency; adjust NPH insulin dose upward during steroid courses; taper NPH concurrently when steroid is reduced

Lexicomp

Moderate ACE Inhibitors / ARBs

MechanismMay enhance insulin sensitivity via improved tissue blood flow and bradykinin-mediated effects

EffectPossible increased hypoglycaemia risk

ManagementMonitor blood glucose more frequently when initiating; insulin dose reduction may be needed

Medscape

Moderate SGLT2 Inhibitors / Sulfonylureas

MechanismAdditive glucose-lowering through independent mechanisms

EffectIncreased hypoglycaemia risk; SGLT2i may additionally contribute to euglycaemic DKA in T1DM

ManagementReduce NPH insulin dose by 10–20% when adding these agents; monitor glucose frequently during co-initiation

FDA PI

Moderate Alcohol (ethanol)

MechanismInhibits hepatic gluconeogenesis; unpredictable glycaemic effect (may increase or decrease glucose)

EffectIncreased risk of delayed and prolonged hypoglycaemia, particularly overnight

ManagementAdvise patients to consume alcohol with food; increase glucose monitoring; educate on symptoms that may mimic intoxication

FDA PI

Minor Fluoroquinolones

MechanismFluoroquinolones may cause unpredictable glucose disturbances (both hypo- and hyperglycaemia)

EffectDysglycaemia during antibiotic course

ManagementIncrease glucose monitoring during fluoroquinolone therapy; adjust insulin as needed

FDA Safety Communication

Mon

Monitoring for NPH Insulin

Blood Glucose (SMBG or CGM) Daily; increase with dose changes
Routine Fasting glucose is the primary titration target for basal NPH insulin. Pre-dinner testing helps guide morning NPH dose. Bedtime and 3 AM checks may be necessary to detect nocturnal hypoglycaemia. CGM is recommended in T1DM and insulin-treated T2DM (ADA 2025).
HbA1c Every 3 months until stable, then every 6 months
Routine Target is individualised: generally <7% for most adults (ADA); <6.5% may be appropriate for selected patients without significant hypoglycaemia risk; <8% for elderly or those with limited life expectancy.
Serum Potassium Baseline; periodically if at risk
Trigger-based Insulin drives potassium intracellularly. Monitor in patients taking loop diuretics, thiazides, or other potassium-lowering medications. Clinically significant in hospitalised patients receiving insulin infusions.
Renal Function Baseline, then annually
Routine Declining renal function reduces insulin clearance. Check serum creatinine and eGFR; dose reduction required with progression of CKD. Annual urinary albumin-to-creatinine ratio is part of standard diabetes care.
Injection Sites Every visit
Routine Examine for lipodystrophy, localised cutaneous amyloidosis, erythema, or induration. Lipohypertrophy is a common cause of erratic glucose control due to unpredictable absorption from affected tissue.
Body Weight Every visit
Routine Track weight trajectory. Insulin promotes weight gain; if progressive, reassess dietary plan and consider adding or continuing metformin or GLP-1 receptor agonist where appropriate.
Retinal Examination Before insulin initiation if not done within past year; annually thereafter
Routine Rapid improvement in glycaemic control can transiently worsen diabetic retinopathy. Baseline retinal assessment establishes the reference point; closer follow-up if pre-existing retinopathy is present.
Hypoglycaemia Awareness Every visit
Trigger-based Assess for impaired hypoglycaemia awareness, especially in patients with longstanding diabetes or recurrent hypos. If impaired awareness is identified, liberalise glucose targets, consider CGM, and re-evaluate NPH versus a long-acting analogue.

Contraindications & Cautions

Absolute Contraindications

During episodes of hypoglycaemia — do not administer NPH insulin when blood glucose is low
Known hypersensitivity to insulin isophane, protamine, or any excipient (metacresol, phenol, zinc)

Relative Contraindications (Specialist Input Recommended)

Protamine allergy or prior protamine exposure (e.g., patients who have received protamine reversal of heparin) — cross-sensitivity with the protamine component of NPH insulin may occur; consider non-protamine-containing basal insulin alternatives
Impaired hypoglycaemia awareness with recurrent severe hypoglycaemia — the pronounced peak and variable absorption profile of NPH insulin heighten risk; long-acting analogues or insulin pump therapy may be preferable
Significantly erratic meal patterns — the NPH peak requires predictable carbohydrate intake to avoid glucose excursions; a peakless basal analogue may be more appropriate

Use with Caution

Renal impairment — reduced insulin clearance requires lower doses and increased monitoring (FDA PI)
Hepatic impairment — reduced gluconeogenesis and insulin degradation capacity; start low, titrate slowly
Elderly patients — conservative initial dosing and titration to avoid hypoglycaemia, which may present atypically and may be harder to recognise (FDA PI)
Concurrent use with thiazolidinediones — dose-dependent fluid retention may precipitate or worsen heart failure
Patients with visual impairment — the KwikPen requires audible clicks for dose selection; ensure the patient can accurately prepare the dose
Changes in physical activity, diet, or concomitant medications — all require reassessment of NPH insulin dose

FDA Class-Wide Safety Advisory — All Insulins Hypoglycaemia and Medication Errors

Accidental mix-ups between insulin products have been reported and may result in serious hypoglycaemia or hyperglycaemia. Patients must always verify the insulin label before each injection. NPH insulin is a cloudy suspension and must be distinguished from clear insulin solutions. Never administer NPH insulin intravenously or use it in an insulin infusion pump. Never share insulin pens, needles, or syringes between patients, even when the needle has been changed, due to risk of bloodborne pathogen transmission.

Patient Counselling

Purpose of Therapy

NPH insulin replaces or supplements the body’s own insulin production. In type 1 diabetes it is a life-sustaining medication; in type 2 diabetes it helps control blood glucose when oral medications alone are insufficient. The goal is to maintain blood glucose within a target range set by the prescriber, thereby reducing long-term complications such as kidney disease, nerve damage, eye problems, and cardiovascular events.

How to Take

NPH insulin is injected under the skin (not into a vein or muscle). Before each injection, gently roll the vial or pen between the palms and invert it several times until the suspension is uniformly cloudy. Do not use if it contains clumps, particles, or appears frosted. Rotate injection sites within the same body region (abdomen, thigh, upper arm, or buttock) to prevent skin changes at the injection site. If mixing NPH with regular insulin in the same syringe, draw the clear insulin first. Inject immediately after mixing.

Low Blood Sugar (Hypoglycaemia)

Tell patient Symptoms include shakiness, sweating, fast heartbeat, dizziness, hunger, confusion, and irritability. Always carry a rapid-acting glucose source (glucose tablets, juice, or sweets). Treat mild episodes with 15 g of fast-acting carbohydrate and recheck in 15 minutes. Hypoglycaemia is more likely if meals are skipped or delayed, after strenuous exercise, or if the dose is too high. NPH insulin peaks 4–12 hours after injection, so plan snacks accordingly, especially before bed.

Call prescriber If experiencing frequent low blood sugar episodes, if unable to recognise hypo symptoms, if severe hypoglycaemia occurs (loss of consciousness, seizure, needing help from another person), or if blood sugar remains low despite treatment.

Injection Technique & Site Rotation

Tell patient Rotate injection sites systematically within the same body region. Do not inject into lumps, scars, or areas of thickened skin. Injecting into the same spot repeatedly causes fatty lumps under the skin (lipodystrophy) that make insulin absorption unpredictable. Always use a new needle for each injection.

Call prescriber If noticing hard lumps, pitting, or unusual skin changes at injection sites; if glucose readings become erratic despite consistent dosing.

Storage & Handling

Tell patient Unopened NPH insulin should be refrigerated (2–8 °C / 36–46 °F). Once in use: Humulin N vials may be kept at room temperature (up to 30 °C / 86 °F) for up to 31 days; Humulin N KwikPens for up to 14 days. Novolin N vials are usable for up to 42 days at room temperature (up to 25 °C / 77 °F); Novolin N FlexPens for up to 28 days (up to 30 °C / 86 °F). Do not freeze and do not expose to direct heat or sunlight. Always check the expiration date and discard expired or discoloured insulin.

Call prescriber If insulin appears frosted, clumped, or discoloured; if uncertain whether insulin has been stored correctly after travel or temperature exposure.

Weight Gain

Tell patient Some weight gain is expected with insulin therapy, typically 1–4 kg in the first year. This occurs because insulin helps the body use and store glucose more efficiently. Maintaining a balanced diet, portion control, and regular physical activity can help limit weight gain.

Call prescriber If weight gain is rapid or excessive (more than 5 kg in a few months), or if concerned about dietary strategies.

Sick Day Rules

Tell patient Never stop NPH insulin during illness, even if unable to eat normally. Illness often raises blood glucose due to stress hormones. Check blood glucose more frequently (every 2–4 hours). Stay hydrated. If vomiting prevents food intake, consume clear liquids with carbohydrates (e.g., regular soda, juice). The dose may need to be adjusted upward or downward depending on glucose readings and food intake.

Call prescriber If blood glucose remains persistently above 250 mg/dL, if ketones are present in urine or blood, if unable to keep fluids down for more than a few hours, or if feeling increasingly unwell.

Driving & Hazardous Activities

Tell patient Hypoglycaemia can impair concentration and reaction time. Check blood glucose before driving and at regular intervals on long journeys. Always keep a glucose source in the vehicle. Do not drive if blood glucose is low or if feeling unwell.

Call prescriber If experiencing hypoglycaemia while driving or operating machinery.

Ref

Sources

Regulatory (PI / SmPC)

Eli Lilly and Company. Humulin N (insulin isophane human injection) U-100 — Full Prescribing Information. Revised 2022. https://pi.lilly.com/us/HUMULIN-N-USPI.pdf Primary US prescribing reference for Humulin N; source for pharmacokinetic parameters, indications, contraindications, and adverse reactions.
Novo Nordisk. Novolin N (insulin isophane human injection) U-100 — Full Prescribing Information. https://www.novo-pi.com/novolinn.pdf Complementary PI for the Novo Nordisk formulation; confirms consistent pharmacodynamic and safety profile across manufacturers.
DailyMed. Humulin N — insulin human injection, suspension. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6edd793-440b-40c2-96b5-c16133b7a921 NLM-hosted label with structured product data used to cross-verify dosing, storage, and safety information.

Guidelines

American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1):S181–S218. https://doi.org/10.2337/dc25-S009 ADA guideline specifying NPH insulin as a suitable basal insulin option; provides starting dose recommendations and comparison with long-acting analogues.
American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes — 2026. Diabetes Care. 2026;49(Suppl 1):S321–S340. https://doi.org/10.2337/dc26-S015 Current ADA guidance listing NPH insulin as a basal insulin option in pregnancy; confirms human insulins do not cross the placenta.
Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012;97(1):16–38. https://doi.org/10.1210/jc.2011-2098 Guideline supporting basal-bolus subcutaneous insulin regimens (including NPH) over sliding-scale-only approaches in non-ICU inpatients.

Key Clinical Trials

Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD005613. https://doi.org/10.1002/14651858.CD005613.pub3 Cochrane review comparing NPH with long-acting analogues; established similar HbA1c reduction but higher nocturnal hypoglycaemia rates with NPH.
Fishel Bartal M, Ward C, Blackwell SC, et al. Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial. Am J Obstet Gynecol. 2021;225(1):87.e1–87.e10. https://doi.org/10.1016/j.ajog.2021.04.223 RCT demonstrating comparable pregnancy outcomes between NPH and insulin detemir, supporting NPH as a safe basal insulin choice in pregnancy.
Lipska KJ, Parker MM, Moffet HH, Huang ES, Karter AJ. Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. JAMA. 2018;320(1):53–62. https://doi.org/10.1001/jama.2018.7993 Large retrospective cohort (25,489 patients) finding no clinically significant difference in hypoglycaemia-related ED visits or HbA1c outcomes between NPH and analogue initiators.

Mechanistic / Basic Science

Hagedorn HC, Jensen BN, Krarup NB, et al. Protamine insulinate. JAMA. 1936;106(3):177–180. https://doi.org/10.1001/jama.1936.02770030007002 Landmark paper describing the original development of protamine-insulin complexes, the foundational chemistry behind NPH insulin.
Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999–1005. https://doi.org/10.2337/diabetes.49.6.999 Characterises receptor binding profiles of human insulin and analogues; contextualises NPH insulin’s pharmacodynamic behaviour relative to newer formulations.

Pharmacokinetics / Special Populations

Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9(5):648–659. https://doi.org/10.1111/j.1463-1326.2007.00756.x Clamp study data demonstrating NPH insulin’s pronounced peak and intra-patient variability compared with peakless basal analogues.
Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): A fast-acting analog of human insulin: Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501–1506. https://doi.org/10.2337/diacare.22.9.1501 Provides pharmacokinetic context for pairing rapid-acting analogues with NPH in basal-bolus regimens.
Rave K, Heise T, Pfützner A, et al. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24(5):886–890. https://doi.org/10.2337/diacare.24.5.886 Demonstrates that declining renal function prolongs insulin action and increases hypoglycaemia risk, supporting dose reduction guidance in CKD.